Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most commonly in EGFR-mutant non-small cell lung cancer, secondary resistance mutations on the target kinase domain emerge to diminish...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Zuan-Fu, Ma, Patrick C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902404/
https://www.ncbi.nlm.nih.gov/pubmed/31815659
http://dx.doi.org/10.1186/s13045-019-0818-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902404/
https://www.ncbi.nlm.nih.gov/pubmed/31815659
http://dx.doi.org/10.1186/s13045-019-0818-2

Ejemplares similares